title: Personalized treatment is better than one treatment fits all in the management of patients with mCRC: a consensus statement.
abstract: The VEGF- (bevacizumab) and EGFR- (cetuximab and panitumumab) targeting monoclonal antibodies have become integral components of the first-line treatment strategies for patients with metastatic colorectal cancer (mCRC). Increasingly combination chemotherapy, with or without a targeted agent, is being used to facilitate curative liver resection and improve survival rates in patients with initially unresectable but potentially resectable mCRC. Currently, the only selective marker for the treatment of patients with mCRC is tumor RAS mutational status. BRAF status is a strong prognostic indicator. Medical and clinical oncologists from Central Asia, Russia, the Middle East, Africa and Turkey reviewed data for the use of targeted agents in the treatment of patients with mCRC and have formed recommendations for the biological of choice first-line for patients with mCRC.
authors.affiliation: Department of Medical Oncology, Hacettepe University Institute of Cancer, Hacettepe University, Ankara, Turkey.
authors.forename: Suayib
authors.initials: S
authors.lastname: Yalcin
authors.forename: Diaeddine
authors.initials: D
authors.lastname: Trad
authors.forename: Yasser Abdel
authors.initials: YA
authors.lastname: Kader
authors.forename: Hafez
authors.initials: H
authors.lastname: Halawani
authors.forename: Osman Gokhan
authors.initials: OG
authors.lastname: Demir
authors.forename: Riaz
authors.initials: R
authors.lastname: Mall
authors.forename: Andrey
authors.initials: A
authors.lastname: Meshcheryakov
authors.forename: Fadi
authors.initials: F
authors.lastname: Nasr
authors.forename: Adam
authors.initials: A
authors.lastname: Nosworthy
authors.forename: Dmitry
authors.initials: D
authors.lastname: Osinsky
authors.forename: Assel
authors.initials: A
authors.lastname: Tumanova
authors.forename: Serdar
authors.initials: S
authors.lastname: Turhal
authors.forename: Sabine
authors.initials: S
authors.lastname: Tejpar
authors.forename: Claus-Henning
authors.initials: CH
authors.lastname: Köhne
mesh_terms: D000911:Antibodies, Monoclonal / Q000235:genetics / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000235:genetics / Q000627:therapeutic use; D000068258:Bevacizumab; D000068818:Cetuximab; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000276:immunology; D006801:Humans; D009362:Neoplasm Metastasis; D015689:Oncogene Protein p21(ras) / Q000235:genetics; D000077544:Panitumumab; D057285:Precision Medicine; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000077544:Panitumumab; C512478:EGFR protein, human; D066246:ErbB Receptors; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; D015689:Oncogene Protein p21(ras); D000068818:Cetuximab
keywords: RAS mutation status; bevacizumab; cetuximab; consensus treatment recommendations; first-line; metastatic colorectal cancer; panitumumab